News & Events about Pyxis Oncology Inc.
Thinking about buying stock in Pyxis Oncology, Kingsoft Cloud, Dermata Therapeutics, Faraday Future Intelligent Electric, or Exela Technologies? Thinking about buying stock in Pyxis Oncology, Kingsoft Cloud, Dermata Therapeutics, Faraday Future Intelligent Electric, or Exela Technologies? PR...
Globe Newswire
2 months ago
Milestone marks transition of Pyxis Oncology to a clinical-stage company Preliminary data anticipated in early 2024 CAMBRIDGE, Mass., March 16, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company focused on developing next-generation therapeutics to target ...
Globe Newswire
3 months ago
CAMBRIDGE, Mass., Feb. 13, 2023 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next-generation therapeutics to target difficult-to-treat cancers, today announced that Lara Sullivan, M.D., President and Chief Executive Officer, Pamela Connealy...
CAMBRIDGE, Mass., May 13, 2022 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a multi-asset multi-modality company focused on developing next-generation therapeutics for difficult to treat cancers, today reported financial results for its first quarter ended March 31, 2022. The Company ...
Pyxis Oncology, Inc. (NASDAQ:PYXS Get Rating) was the target of a large decline in short interest during the month of April. As of April 15th, there was short interest totalling 421,500 shares, a decline of 21.7% from the March 31st total of 538,500 shares. Approximately 2.1% of the shares ...